  ABSTRACT
Despite the availability of highly active antiretroviral therapy (HAART) for the treatment of human immunodefi ciency virus (HIV) infection, there has not been a dramatic decrease in the frequency of progressive multifocal leukoencephalopathy (PML) in the HIV-infected population. Usually a multifocal progressive disease of nonenhancing lesions in white matter, PML can have distinct characteristics in HIV-infected patients, including unifocal static lesions of faint contrast enhancement on imaging and involvement of gray matter. A syndrome of cerebellar degeneration has been described in association with HIV infection in patients positive for JC virus, the papovavirus responsible for PML. The standard of care for HIV-associated PML is HAART to achieve immunologic recovery and optimal HIV virologic control. The prognosis of PML has improved greatly since the advent of HAART.
T he appearance of progressive multifocal leukoencephalopathy (PML) as a complication of human immunodefi ciency virus (HIV) infection dates to shortly after the fi rst description of acquired immunodefi ciency syndrome (AIDS). The advent of highly active antiretroviral therapy (HAART) dramatically altered the nature of HIV infection, resulting in a substantial decline in mortality and, in essence, turning AIDS into a chronic disease. As patients lived longer with HIV infection, one consequence was an increased incidence of neurologic complications. By the early 1980s, AIDS was well recognized as an underlying disorder that predisposed to PML.
As many as 70% of HIV patients will eventually have involvement of either the peripheral or central nervous system (CNS). Most patients with HIV are managed by primary care clinicians, including those in the fi elds of family practice, internal medicine, or infectious disease, and the complexity of the neurologic disorders associated with HIV often results in either delayed diagnosis or misdiagnosis. For example, the evolution of HIV in the plasma, where most clinicians measure it, may differ from its evolution in the spinal fl uid and brain. An emerging issue is that of hepatitis C coinfection, which may itself be associated with central and peripheral neuro logic complications.
Treatment of HIV with antiretroviral agents has numerous neurologic implications. These include the potential ability of these agents to penetrate the bloodbrain barrier, their effi cacy in both treating and preventing cognitive impairment and other CNS disorders, and their toxic effects in the CNS and peripheral nervous system.
  NEUROLOGIC COMPLICATIONS OF AIDS
Neurologic disease in AIDS patients can be classifi ed in several ways. One of the most logical, particularly for primary care clinicians, is the separation of primary from secondary neurologic disorders:
• Primary neurologic disorders are enigmatic and diffi cult to characterize; they include HIV-associated neurocognitive disorders in adults, encephalopathy in children, myelopathy or spinal cord disease, and peripheral neuropathy.
• Secondary complications are related to progressive immunosuppression. These include opportunistic infections such as cytomegalovirus, toxoplasmosis, or cryptococcal meningitis; and neoplasms such as primary CNS lymphoma. Opportunistic infections and neoplasms have declined in incidence in the HAART era.
The prevalence of neuropathy as a neurologic complication of HIV/AIDS is as high as 57%, while PML affects 5% or fewer of HIV-infected patients (Table) . PML in these patients is often associated with advanced disease, as refl ected by low CD4+ cell counts and increased plasma HIV viral loads.
  AT-RISK POOLS FOR PML
The AIDS epidemic signifi cantly changed the epidemiology of PML, turning a formerly rare disease into a much more common one. In South Florida, the incidence of PML in patients with AIDS increased by 12 times from 
  UNIQUE PRESENTATION OF HIV-ASSOCIATED PML
The brain lesion in PML is classically a nonenhancing focal lesion, preferentially in white matter, but lesion characteristics often depart from this characteristic picture. For example, relatively faint contrast enhancement of lesions on magnetic resonance imaging has been observed, as well as involvement of white matter and gray matter. The distribution and character of brain lesions in PML may also differ from the classic picture. For example, the lesion may not be focal, particularly when PML is combined with the symmetric white matter abnormalities that are seen in HIV encephalopathy; this nonclassic presentation can cause diffi culty in radiologic differentiation of PML and HIV encephalopathy. 
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  MANAGEMENT OF HIV-ASSOCIATED PML
Optimize HAART A suppressed plasma HIV viral load is the strongest prognostic factor for an improved course in PML. 4 In the pre-HAART era, the mean survival of HIV-associated PML was 3 to 6 months, with long-term survival estimated at 10%. 5 The use of HAART has achieved a dramatic improvement in long-term survival, to upwards of 50%. 6 Neurologic defi cits are often irreversible even with HAART, but most HAART recipients show stability in neurologic status for years.
Other key characteristics associated with improved survival in HIV-associated PML appear to be younger age, PML as the heralding manifestation of AIDS, initiation of HAART upon diagnosis of PML, higher CD4 count, and absence of severe neurologic impairment.
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Investigational therapies Specifi c antiviral drug regimens targeting JCV have been tested empirically in case studies and in clinical trials in patients with AIDS-and non-AIDS-related PML.
Cytosine arabinoside (Ara-C). Ara-C is a nucleoside analog used as an antineoplastic agent; it terminates chain elongation and inhibits DNA polymerase to confer antiviral activity. Ara-C decreased JCV replication in vitro. 8 Based on anecdotal reports of effi cacy in cancer-related cases of PML,
9 Ara-C was tested in a multicenter trial of 57 patients with HIV and biopsy-confi rmed PML. 10 Neither intravenous nor intrathecal Ara-C combined with established antiviral therapy for AIDS improved the prognosis of these patients, and Ara-C has since been abandoned as a strategy to treat HIV-related PML.
Cidofovir. The noncyclic nucleoside phosphonate cidofovir garnered attention as a potential treatment for 
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PML based on case reports of effi cacy in HIV as well as non-HIV patients. Subsequently, a large multicenter study failed to detect any signifi cant added benefi t with cidofovir beyond that of HAART. 11 Retrospective European studies confi rmed the lack of clinical benefi t with cidofovir. 6, 7, 12 Interferon alfa. Case reports with interferon alfa2a and -2b for the treatment of PML show confl icting results with respect to clinical response, symptomatic improvement, and survival, but toxicity has been substantial. In a series of 97 patients with AIDS-related PML, Geschwind et al determined that interferon alfa had no effect on survival beyond that of HAART.
13
Mirtazapine. Serotonin receptor antagonists such as mirtazapine can block JCV entry into glial cells via serotonin 5-hydroxytryptamine receptors, providing a rationale for their use as a potential treatment for PML. Verma et al describe a case of clinical improvement (stable neurologic defi cit) and PML lesion regression in a 63-year-old bedbound woman with polycythemia vera with biopsy-proven non-HIV-related PML that had progressed to quadriparesis. 14 Mefl oquine. The antimalarial drug mefl oquine inhibits viral replication in cultured human glial cells and astrocytes, inhibits JC viral DNA replication, and showed effi cacy against two JCV strains in cell culture. 15 A randomized study to assess the effectiveness of mefl oquine for treatment of PML has been completed and its results await publication.
  SUMMARY
The incidence of PML has remained unchanged from the pre-HAART to the HAART era, but the prognosis is greatly improved. The clinical presentation of PML in AIDS patients may deviate from the classic triad of progressive, multifocal, white matter disease. It may be static and unifocal, and it may involve gray matter and neurons as well as white matter. The number of neurologic manifestations is vast and can include the cerebellar syndrome. Lumbar puncture with a PCR negative for JCV does not confi rm the absence of PML.
The standard of care for HIVassociated PML is HAART, with the goal of achieving immunologic recovery and optimal virologic control. Whether therapeutic results obtained in patients with HIV-associated PML can be translated to the setting of non-HIVassociated PML is unclear.
  DISCUSSION
Dr. Simpson:
As a followup to the Ara-C trial that was published, 10 PML confi rmed by brain biopsy was one of the enrolling criteria, and the planned study population was 65 patients. Longitudinal examination of viral load in cerebrospinal fl uid (CSF) was a part of the study, and we found that the lower the viral load, the better the prognosis. Fifty-two patients were enrolled before the trial was stopped because it was clear that Ara-C was not producing a benefi t. The patients had multifocal disease but, because Ara-C does not effectively cross the bloodbrain barrier, penetration in the brain was minimal even with the use of an intrathecal shunt in this study. Dr. Bennett: How is it that the incidence of PML has not changed from the pre-HAART to the post-HAART era? How do you account for this in terms of the change in patients' T-cell function from pre-to post-HAART?
Dr. Simpson: I don't know. Intuitively, why do patients treated with HAART, who are relatively immune reconstituted, develop PML? The problem is that not everyone is immune reconstituted. HAART fails in some patients. Further, PML remains a disease that is 
